Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 01 04:00PM ET
32.23
Dollar change
+0.04
Percentage change
0.12
%
IndexRUT P/E- EPS (ttm)-0.99 Insider Own3.49% Shs Outstand113.86M Perf Week0.00%
Market Cap3.70B Forward P/E- EPS next Y-0.95 Insider Trans-8.09% Shs Float110.78M Perf Month37.09%
Income-105.37M PEG- EPS next Q-0.32 Inst Own99.33% Short Float7.56% Perf Quarter71.62%
Sales31.07M P/S119.07 EPS this Y-45.94% Inst Trans-0.91% Short Ratio2.27 Perf Half Y133.89%
Book/sh2.57 P/B12.56 EPS next Y34.54% ROA-36.55% Short Interest8.37M Perf Year294.01%
Cash/sh3.43 P/C9.38 EPS next 5Y- ROE-64.17% 52W Range7.26 - 32.33 Perf YTD36.45%
Dividend Est.- P/FCF- EPS past 5Y4.59% ROI-26.56% 52W High-0.31% Beta0.32
Dividend TTM- Quick Ratio10.96 Sales past 5Y0.00% Gross Margin97.81% 52W Low343.88% ATR (14)0.64
Dividend Ex-Date- Current Ratio10.96 EPS Y/Y TTM17.84% Oper. Margin-327.23% RSI (14)80.99 Volatility0.34% 1.80%
Employees101 Debt/Eq0.39 Sales Y/Y TTM- Profit Margin-339.10% Recom2.83 Target Price30.61
Option/ShortYes / Yes LT Debt/Eq0.36 EPS Q/Q-21.93% Payout- Rel Volume0.95 Prev Close32.19
Sales Surprise-86.59% EPS Surprise-12.58% Sales Q/Q- EarningsFeb 28 AMC Avg Volume3.69M Price32.23
SMA209.31% SMA5024.64% SMA20093.33% Trades Volume3,497,707 Change0.12%
Date Action Analyst Rating Change Price Target Change
Feb-13-24Downgrade Raymond James Outperform → Mkt Perform
Aug-14-23Initiated UBS Buy $18
Aug-11-23Initiated Guggenheim Buy $20
Apr-05-23Initiated William Blair Outperform
Mar-09-23Initiated BTIG Research Buy $15
Apr-11-22Resumed Cantor Fitzgerald Overweight $9
Aug-04-20Reiterated H.C. Wainwright Buy $9 → $13
Jul-31-20Initiated Piper Sandler Overweight $12
May-26-20Upgrade H.C. Wainwright Neutral → Buy $9
May-12-20Upgrade SVB Leerink Mkt Perform → Outperform $6
Feb-28-24 06:10PM
04:45PM
Feb-21-24 05:43PM
Feb-20-24 04:05PM
Feb-15-24 03:01AM
04:15PM Loading…
Feb-12-24 04:15PM
01:43PM
01:27PM
12:34PM
12:27PM
12:03PM
09:57AM
09:45AM
09:18AM
08:45AM
08:44AM Loading…
08:44AM
08:42AM
08:38AM
08:33AM
08:30AM
Jan-31-24 08:00AM
Jan-22-24 11:47PM
Jan-17-24 05:01AM
Jan-16-24 04:28PM
Jan-12-24 05:02AM
Jan-03-24 08:00AM
Jan-02-24 08:00AM
Dec-28-23 12:15PM
Dec-19-23 01:01PM
Dec-18-23 04:05PM
11:01AM Loading…
Dec-16-23 11:01AM
Dec-15-23 08:00AM
Dec-01-23 09:30AM
Nov-18-23 01:03AM
Nov-17-23 04:15PM
Nov-15-23 11:03PM
Nov-13-23 08:00AM
Nov-09-23 03:27PM
Nov-08-23 09:55AM
Nov-07-23 04:04PM
Nov-06-23 08:00AM
Nov-01-23 08:00AM
Oct-31-23 04:05PM
Oct-26-23 09:40AM
Oct-25-23 08:50AM
Oct-23-23 06:16PM
04:05PM
08:00AM
Oct-19-23 05:01AM
Oct-18-23 08:00AM
Oct-16-23 04:05PM
Oct-10-23 11:01PM
Sep-27-23 09:24PM
Sep-21-23 04:39PM
08:00AM
Sep-20-23 01:01AM
Sep-15-23 08:00AM
Sep-14-23 04:57PM
Sep-12-23 05:37PM
Sep-11-23 10:15PM
06:31PM
06:00AM
Sep-08-23 04:49PM
01:12PM
11:59AM
Sep-07-23 07:00AM
Sep-06-23 04:05PM
Aug-28-23 04:29PM
Aug-12-23 08:48AM
Aug-11-23 09:36AM
Aug-10-23 04:04PM
08:00AM
Aug-03-23 04:05PM
Jul-17-23 08:50AM
Jun-30-23 11:50AM
Jun-24-23 03:19PM
Jun-21-23 03:00AM
Jun-07-23 02:00AM
May-19-23 05:59PM
May-16-23 11:06AM
08:50AM
May-15-23 04:04PM
May-10-23 08:00AM
May-09-23 08:00AM
Apr-28-23 07:00AM
Apr-26-23 10:01AM
Apr-21-23 08:00AM
Apr-17-23 08:00AM
Mar-29-23 08:50AM
Mar-28-23 09:55AM
Mar-20-23 09:04PM
Mar-18-23 08:31AM
Mar-16-23 04:04PM
Mar-09-23 04:05PM
Mar-01-23 08:00AM
Feb-06-23 08:00AM
Jan-30-23 08:00AM
Jan-24-23 07:00AM
Jan-23-23 04:11PM
Jan-17-23 08:50AM
CymaBay Therapeutics, Inc. engages in the provision and development of access to therapies for patients with liver and other chronic diseases with high unmet medical needs. Its products pipeline includes Seladelpar, MBX-2982, CB-0406, and CB-001. The company was founded on October 5, 1988 and is headquartered in Newark, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Dorling JanetDirectorFeb 12Option Exercise4.636,00027,7806,000Feb 14 06:43 PM
Dorling JanetDirectorFeb 12Sale31.976,000191,8490Feb 14 06:43 PM
McWherter CharlesPresident of R&DJan 19Option Exercise7.0918,403130,52223,334Jan 22 06:59 PM
McWherter CharlesPresident of R&DJan 19Sale23.6718,403435,64515,000Jan 22 06:59 PM
Menold DanielVice President, FinanceJan 16Option Exercise4.0510,00040,50010,000Jan 16 07:07 PM
Quinlan Paul TGeneral CounselJan 16Option Exercise2.945,00014,7005,000Jan 16 07:07 PM
Menold DanielVice President, FinanceJan 16Sale23.5810,000235,8060Jan 16 07:07 PM
Quinlan Paul TGeneral CounselJan 16Sale23.585,000117,8980Jan 16 07:07 PM
Dorling JanetDirectorJan 10Option Exercise4.636,00027,7806,000Jan 10 08:35 PM
Dorling JanetDirectorJan 10Sale23.866,000143,1440Jan 10 08:35 PM
McWherter CharlesPresident of R&DDec 18Option Exercise5.0011,33256,66021,504Dec 18 08:04 PM
McWherter CharlesPresident of R&DDec 18Sale21.4811,332243,44115,000Dec 18 08:04 PM
Menold DanielVice President, FinanceDec 15Option Exercise6.3921,497137,42011,497Dec 15 04:38 PM
Quinlan Paul TGeneral CounselDec 15Option Exercise2.945,00014,7005,000Dec 15 04:35 PM
Menold DanielVice President, FinanceDec 15Sale21.9921,497472,6460Dec 15 04:38 PM
Quinlan Paul TGeneral CounselDec 15Sale21.985,000109,9020Dec 15 04:35 PM
Shah SujalChief Executive OfficerDec 11Option Exercise5.0064,865324,325235,276Dec 11 07:03 PM
Dorling JanetDirectorDec 11Option Exercise4.636,00027,7806,000Dec 11 07:01 PM
Shah SujalChief Executive OfficerDec 11Sale20.0064,8651,297,170171,301Dec 11 07:03 PM
Dorling JanetDirectorDec 11Sale20.076,000120,4220Dec 11 07:01 PM
McWherter CharlesPresident of R&DNov 17Option Exercise5.0011,34256,71026,342Nov 17 05:58 PM
McWherter CharlesPresident of R&DNov 17Sale18.2811,342207,29315,000Nov 17 05:58 PM
Menold DanielVice President, FinanceNov 15Option Exercise3.4517,50060,37517,500Nov 17 05:57 PM
Quinlan Paul TGeneral CounselNov 15Option Exercise2.945,00014,7005,000Nov 17 05:57 PM
Quinlan Paul TGeneral CounselNov 15Sale17.385,00086,8890Nov 17 05:57 PM
McWherter CharlesPresident of R&DOct 18Option Exercise5.0021,743108,71536,743Oct 18 06:22 PM
McWherter CharlesPresident of R&DOct 18Sale14.0721,743305,94115,000Oct 18 06:22 PM
Menold DanielVice President, FinanceOct 16Option Exercise3.4517,50060,37517,500Oct 18 06:22 PM
Quinlan Paul TGeneral CounselOct 16Option Exercise2.945,00014,7005,000Oct 18 06:21 PM
Quinlan Paul TGeneral CounselOct 16Sale13.765,00068,7980Oct 18 06:21 PM
Shah SujalChief Executive OfficerOct 09Option Exercise5.0064,861324,305236,162Oct 10 05:04 PM
Shah SujalChief Executive OfficerOct 09Sale14.2064,861921,286171,301Oct 10 05:04 PM
EMSTER KURT VONDirectorSep 29Option Exercise5.0015,92179,605105,921Sep 29 05:54 PM
EMSTER KURT VONDirectorSep 29Sale15.6815,921249,67590,000Sep 29 05:54 PM
McWherter CharlesPresident of R&DSep 18Option Exercise5.0021,746108,73036,746Sep 19 05:27 PM
McWherter CharlesPresident of R&DSep 18Sale16.2221,746352,73315,000Sep 19 05:27 PM
Quinlan Paul TGeneral CounselSep 15Option Exercise2.9453,000155,82024,000Sep 19 05:23 PM
Menold DanielVice President, FinanceSep 15Option Exercise1.7316,54528,61215,000Sep 19 05:25 PM
Quinlan Paul TGeneral CounselSep 15Sale16.8753,000894,1410Sep 19 05:23 PM
McWherter CharlesPresident of R&DAug 18Option Exercise5.0021,746108,73036,746Aug 18 07:03 PM
McWherter CharlesPresident of R&DAug 18Sale11.4721,746249,35915,000Aug 18 07:03 PM
Menold DanielVice President, FinanceAug 15Option Exercise5.1015,50079,0108,500Aug 16 04:59 PM
Quinlan Paul TGeneral CounselAug 15Option Exercise2.945,00014,7005,000Aug 16 04:57 PM
Quinlan Paul TGeneral CounselAug 15Sale11.915,00059,5500Aug 16 04:57 PM
Menold DanielVice President, FinanceAug 09Option Exercise5.0020,945104,72520,945Aug 11 06:26 PM
Menold DanielVice President, FinanceAug 09Sale12.3520,945258,7440Aug 11 06:26 PM
McWherter CharlesPresident of R&DJul 18Option Exercise5.0021,749108,74536,749Jul 19 06:05 PM
McWherter CharlesPresident of R&DJul 18Sale11.4321,749248,51915,000Jul 19 06:05 PM
Quinlan Paul TGeneral CounselJul 14Option Exercise2.945,00014,7005,000Jul 14 06:52 PM
Quinlan Paul TGeneral CounselJul 14Sale11.815,00059,0500Jul 14 06:52 PM
Quinlan Paul TGeneral CounselJun 30Option Exercise2.945,00014,7005,000Jun 30 04:51 PM
Quinlan Paul TGeneral CounselJun 30Sale10.055,00050,2500Jun 30 04:51 PM
McWherter CharlesPresident of R&DJun 20Option Exercise5.0021,749108,74536,749Jun 21 06:46 PM
McWherter CharlesPresident of R&DJun 20Sale8.1621,749177,38315,000Jun 21 06:46 PM
McWherter CharlesPresident of R&DMay 18Option Exercise5.0021,749108,74536,749May 19 06:00 PM
McWherter CharlesPresident of R&DMay 18Sale9.0821,749197,38715,000May 19 06:00 PM
Quinlan Paul TGeneral CounselMay 15Option Exercise2.945,00014,7005,000May 17 07:11 PM
Quinlan Paul TGeneral CounselMay 15Sale10.375,00051,8310May 17 07:11 PM
KIM DENNIS DChief Medical OfficerApr 17Option Exercise4.37112,219490,397132,219Apr 17 07:24 PM
KIM DENNIS DChief Medical OfficerApr 17Sale9.54112,2191,070,53620,000Apr 17 07:24 PM
KIM DENNIS DChief Medical OfficerApr 13Option Exercise4.377,78134,00327,781Apr 17 07:24 PM
KIM DENNIS DChief Medical OfficerApr 13Sale8.987,78169,88020,000Apr 17 07:24 PM
KIM DENNIS DChief Medical OfficerMar 28Option Exercise4.3710043720,100Mar 30 05:39 PM
KIM DENNIS DChief Medical OfficerMar 28Sale8.9810089820,000Mar 30 05:39 PM